Revised SPC: Tecentriq (atezolizumab) 840 mg concentrate for solution for infusion

SPC updated with additional indication - treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy, in combination with bevacizumab.

electronic Medicines compendium